Title |
Lithium and GSK-3β promoter gene variants influence cortical gray matter volumes in bipolar disorder
|
---|---|
Published in |
Psychopharmacology, October 2014
|
DOI | 10.1007/s00213-014-3770-4 |
Pubmed ID | |
Authors |
Francesco Benedetti, Sara Poletti, Daniele Radaelli, Clara Locatelli, Adele Pirovano, Cristina Lorenzi, Benedetta Vai, Irene Bollettini, Andrea Falini, Enrico Smeraldi, Cristina Colombo |
Abstract |
Lithium is the mainstay for the treatment of bipolar disorder (BD) and inhibits glycogen synthase kinase-3β (GSK-3β). The less active GSK-3β promoter gene variants have been associated with less detrimental clinical features of BD. GSK-3β gene variants and lithium can influence brain gray and white matter structure in psychiatric conditions, so we studied their combined effect in BD. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 33% |
Saudi Arabia | 1 | 17% |
Canada | 1 | 17% |
Unknown | 2 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 6 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 70 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 70 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 15 | 21% |
Researcher | 10 | 14% |
Student > Ph. D. Student | 9 | 13% |
Other | 8 | 11% |
Student > Doctoral Student | 5 | 7% |
Other | 8 | 11% |
Unknown | 15 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Neuroscience | 12 | 17% |
Medicine and Dentistry | 10 | 14% |
Psychology | 9 | 13% |
Biochemistry, Genetics and Molecular Biology | 4 | 6% |
Agricultural and Biological Sciences | 3 | 4% |
Other | 9 | 13% |
Unknown | 23 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 March 2016.
All research outputs
#12,711,586
of 22,768,097 outputs
Outputs from Psychopharmacology
#3,831
of 5,341 outputs
Outputs of similar age
#115,472
of 260,390 outputs
Outputs of similar age from Psychopharmacology
#24
of 58 outputs
Altmetric has tracked 22,768,097 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,341 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 260,390 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
We're also able to compare this research output to 58 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.